AN OPEN LABEL, PROSPECTIVE, MULTICENTRIC, PHASE-III CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY IN PATIENTS TREATED WITH rhG-CSF THERAPY AT HIGH RISK FOR MYELOSUPPRESSIVE CHEMOTHERAPY INDUCED NEUTROPENIA.?

G C CHEMIE PHARMIE0 个研究点目标入组 50 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 3 期
状态: 已完成
发起方
入组人数: 50

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•Cancer patients of either sex under the age group of 18-70 yrs, receiving Myelosuppressive chemotherapy
•Patient not receiving any rhG-CSF therapy.
•Haematological Investigation
•- Absolute neutrophil count >=1500 /mm3
•-Haemoglobin at least 9.0 g/dL
•-Platelet count at least 100,000/mm3
•-Bilirubin less than 2.5 times upper limit of normal (ULN)
•-SGPT less than 5 times ULN
•-Creatinine normal OR < 1.5 Ã? upper limit of normal
•Cardiovascular
•-Ejection fraction normal by MUGA or echocardiogram
•Be able to provide signed informed consent.
•Women of childbearing potential have a negative urine pregnancy test at the Screening Visit. Furthermore, they must be using a medically accepted method of birth control (i.e., oral, parenteral or implanted contraceptive for at least one month prior to study entry; IUD in place for at least one month prior to study entry; or spermicidal plus barrier methods) and agree to continue to use their present method of birth control throughout the study.

排除标准

•Patient receiving rhG-CSF therapy prior to the study.
•Known or suspected hypersensitivity to the study drug or its components, such as avian products, including influenza vaccine, or to E. coli-derived proteins.
•Pregnant or lactating woman.
•History or clinical evidence of a serious medical illness, including renal, hepatic, respiratory, cardiovascular, endocrine, neurologic, psychiatric, or hematologic disease, which in the opinion of the investigator will interfere with study participation.
•Total lifetime exposure to doxorubicin >240 mg/m2 or epirubicin >600 mg/m2
•Prior bone marrow or stem cell transplantation
•Metastatic brain or meningeal tumors.
•Ascites or pleural effusions.
•Any active infection requiring systemic antimicrobial therapy
•Currently receiving radiation therapy for treatment of a malignant condition, or have completed radiation therapy within 14 days before study entry. Radiation therapy for oncologic emergency is allowed.
•Participated in another therapeutic clinical study (i.e., not an epidemiological study or to simultaneously participate in another therapeutic clinical study. genomic screening study) during the past 30 days, or are likely
•Have known drug or alcohol dependence
•History of hypertensive encephalopathy, stroke or transient ischemic attack (TIA) within the past twelve (12) months
•History or evidence of myocardial infarction, unstable angina pectoris, or stable angina within the past six (6) months.
•History or evidence of gastrointestinal disease or surgery, which might interfere with drug absorption.
•Have any clinically significant abnormalities on pre-study laboratory screening evaluations.
•Are mentally incompetent or unable or unwilling to provide informed consent or comply with study procedures.
•Have any condition or situation that, in the opinion of the investigator, would prevent proper evaluation of the safety of the study drug according to the study protocol (e.g., poorly compliant subject).

研究者

发起方

G C CHEMIE PHARMIE

相似试验

进行中（未招募）

1 期

Prospective study in patients with cancer of the colon or rectum with liver metastasis, of the efficacy and toxicity of standard therapy (chemotherapy + targeted therapy) combined with immunotherapy and internal radiotherapy targeting the liverMICROSATELLITE STABLE (MSS) COLORECTAL CANCER WITH LIVER-DOMINANT METASTASIS

EUCTR2019-002400-40-FRFédération Francophone de Cancérologie Digestive52

进行中（未招募）

不适用

A PHASE II, OPEN-LABEL, PROSPECTIVE, MULTICENTER STUDYTO EVALUATE THE EFFICACY AND SAFETY OF SUBSEQUENTTREATMENT WITH THE ZEVALIN (IBRITUMOMAB TIUXETAN)IN ELDERLY ( 60 YEARS) PATIENTS WITH DIFFUSE LARGE BCELLLYMPHOMA AFTER 4 CYCLES OF CHOP21 ?RITUXIMAB(CHOP21-R) THERAPY. - ND

EUCTR2006-004851-39-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI

招募中

1 期

A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II-TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ZANUBRUTINIB (BGB-3111), A BTK INHIBI-TOR, PLUS TISLELIZUMAB (BGB-A317), A PD-1 INHIBITOR, WITH AND WITH-OUT SONROTOCLAX (BGB-11417), A BCL2 INHIBITOR, FOR TREATMENT OF PATIENTS WITH RICHTER TRANSFORMATION - CLL-RT1-Trial

CTIS2023-504653-12-00niversity Of Cologne85

进行中（未招募）

不适用

PHASE II OPEN LABEL, MULTICENTER, PROSPECTIVE,RELATED MACULAR DEGENERATION, COMPARATOR STUDY EVALUATING PF-04523655 VERSUS RANIBIZUMAB TREATMENT OF SUBJECTS WITH CHOROIDAL NEOVASCULARIZATION (MONET STUDY)Subfoveal Choroidal Neovascularization (CNV) associated with Age-related Macular Degeneration (AMD)MedDRA version: 9.1Level: LLTClassification code 10060837Term: Choroidal neovascularization

EUCTR2008-003210-10-ATPfizer Inc., 235 East 42nd Street, New York, NY 10017280

进行中（未招募）

1 期

EUCTR2008-003210-10-DKPfizer Inc., 235 East 42nd Street, New York, NY 10017280